View Older Stories View More Recent Stories

Oct 14, 2016 08:30AM Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community
Oct 10, 2016 09:17AM Pre-Open Stock Movers 10/10: (IPCI) (TSRO) (MYL) Higher; (TWTR) (BMY) (DOV) Lower (more...)
Oct 10, 2016 06:35AM Pfizer (PFE) Presents Encouraging New Data for INLYTA Combo Phase 1b in Adv. RCC
Oct 10, 2016 06:27AM Merck (MRK) Announces Strong KEYTRUDA Data in NSCLC at ESMO 2016; Superior OS Noted
Oct 9, 2016 02:16AM Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell L
Oct 9, 2016 02:15AM KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to
Oct 8, 2016 08:45AM Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
Oct 8, 2016 02:15AM New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients
Oct 7, 2016 04:06PM Merck Animal Health (MRK) Receives USDA Approval of Canine Flu Bivalent Vaccine
Oct 7, 2016 04:05PM Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine
Oct 7, 2016 05:40AM Incyte (INCY) Issues Updates on Epacadostat + Keytruda Phase 1; Says Median PFS Not Reached (MRK)
Oct 3, 2016 08:00AM Merck to Present New Data on ZEPATIER™ (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting® 2016
Sep 29, 2016 01:06PM Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness
Sep 28, 2016 06:46AM Merck (MRK) Says Extensive KEYTRUDA Data Accepted for Presentation at ESMO
Sep 28, 2016 06:45AM Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented
Sep 28, 2016 06:16AM Incyte (INCY) Announces Publication of Updated Phase 1 Data on Epacadostat + Keytruda in Advanced Melanoma (MRK)
Sep 23, 2016 08:00AM Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25
Sep 20, 2016 08:30AM Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights
Sep 15, 2016 08:33AM Pfizer (PFE), Merck (MRK) Announce Ertugliflozin Phase 3 Met Primary Endpoint in T2D
Sep 15, 2016 08:31AM Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Sep 13, 2016 09:00AM Merck Publishes 2015/2016 Global Corporate Responsibility Report
Sep 9, 2016 08:00AM Merck to Participate at the Morgan Stanley Global Healthcare Conference
Sep 7, 2016 06:49AM Merck (MRK) Announces FDA Accepts BLA with Priority Review and Grants Breakthrough Therapy Designation for KEYTRUDA for NSCLC
Sep 7, 2016 06:48AM Merck's (MRK) KEYTRUDA sBLA in NSCLC Accepted for FDA Priority Review
Sep 7, 2016 06:45AM FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients
Sep 2, 2016 07:01AM Merck (MRK) to Discontinue Development of Odanacatib for Osteoporosis
Sep 2, 2016 07:00AM Merck Provides Update on Odanacatib Development Program
Aug 8, 2016 05:06PM Merck (MRK) Announces Publication of Strong ZEPATIER Phase 3 Data as HCV Treatment
Aug 8, 2016 05:05PM Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Me
Aug 8, 2016 06:45AM REPEAT/FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemot
Aug 8, 2016 06:22AM Merck (MRK) Announces FDA Approval of KEYTRUDA as HNSCC Treatment
Aug 5, 2016 07:30PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Aug 5, 2016 08:04AM Merck (MRK) Announces FDA Filing Acceptance of NDA for MK-1293
Aug 5, 2016 08:00AM Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine
Aug 2, 2016 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Jul 29, 2016 06:45AM Merck Announces Second-Quarter 2016 Financial Results
Jul 26, 2016 12:50PM Merck Announces Fourth-Quarter 2016 Dividend
Jul 25, 2016 08:00AM Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
Jul 22, 2016 07:02AM Merck (MRK) Reports Statistically non-Inferior Data from ISENTRESS Phase 3 in HIV-1
Jul 22, 2016 07:00AM Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
Jul 21, 2016 05:02PM Merck (MRK) Animal Health Announces FDA Approval of BRAVECTO
Jul 21, 2016 05:00PM Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs
Jul 21, 2016 04:33PM Merck (MRK) Provides Regulatory Update on BLA for Bezlotoxumab; Says FDA Requested Submission of New Data and Analyses from MODIFY Trials
Jul 21, 2016 04:30PM Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab
Jul 6, 2016 08:02AM Pfizer (PFE), Merck (MRK) Commence Aveluma Combo Phase 3 in Ovarian Cancer
Jul 1, 2016 12:07PM Merck Animal Health to Acquire Controlling Vallée S.A. Stake in $400M Deal (MRK)
Jul 1, 2016 12:05PM Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.
Jun 30, 2016 08:31AM Premier (PINC), Merck (MRK) Enter Osteoporosis-Focused Collaboration
Jun 30, 2016 08:31AM Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients
Jun 29, 2016 07:00AM Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer
View More Recent Stories View Older Stories